GTCM
KALA icon

Gyon Technologies Capital Management’s KALA BIO KALA Stock Holding History

Gyon Technologies Capital Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8
Closed -$202K – 289
2020
Q2 		$202K Buy
+8
New +$227K 0.49% 62

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gyon Technologies Capital Management's KALA Position: Q3 2020 in Review

Gyon Technologies Capital Management sold out of KALA BIO (KALA) in Q3 2020, closing a stake of 8 shares — an estimated $202K sold.

Gyon Technologies Capital Management first reported a position in KALA in Q2 2020 and held it in 1 quarter. The position peaked at $202K in Q2 2020. 105 funds tracked by Wall St. Rank hold KALA as of Q3 2020.

  • Gyon Technologies Capital Management reported no remaining KALA BIO position as of Q3 2020 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 8 KALA BIO shares in Q3 2020, an estimated $202K.
  • Gyon Technologies Capital Management first reported a position in KALA BIO in Q2 2020 and held it in 1 quarter.
  • Gyon Technologies Capital Management's KALA BIO position peaked at $202K in Q2 2020.
  • 105 funds tracked by Wall St. Rank held KALA BIO as of Q3 2020.

Based on Gyon Technologies Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.